alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AT JUNE 30, 2000 (UNAUDITED) AND THE STATEMENT OF OPERATIONS FOR THE SIX
MONTHS ENDED JUNE 30, 2000 (UNAUDITED) AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<MULTIPLIER>                    1
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               JUN-30-2000
<CASH>                                       1,008,690
<SECURITIES>                                         0
<RECEIVABLES>                                  677,761
<ALLOWANCES>                                   (10,126)
<INVENTORY>                                    826,500
<CURRENT-ASSETS>                             3,081,921
<PP&E>                                       1,403,351
<DEPRECIATION>                                 880,224
<TOTAL-ASSETS>                              12,880,591
<CURRENT-LIABILITIES>                        3,357,248
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                 38,853,219
<COMMON>                                        33,508
<OTHER-SE>                                 (35,301,767)
<TOTAL-LIABILITY-AND-EQUITY>                12,880,591
<SALES>                                      1,458,871
<TOTAL-REVENUES>                             1,458,871
<CGS>                                          788,336
<TOTAL-COSTS>                                4,580,860
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             563,452
<INCOME-PRETAX>                            (10,772,040)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         (4,265,220)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (10,772,040)
<EPS-BASIC>                                      (3.24)
<EPS-DILUTED>                                    (3.24)


</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Condensed Balance Sheet at March 31, 1998 and the Condensed Statement of
Operations for the Three Months Ended March 31, 1998 and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<RESTATED>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                         120,615
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             2,044,244
<PP&E>                                       1,697,973
<DEPRECIATION>                                 985,658
<TOTAL-ASSETS>                              11,221,998
<CURRENT-LIABILITIES>                        6,110,935
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                 15,619,880
<COMMON>                                        25,794
<OTHER-SE>                                (12,544,510)
<TOTAL-LIABILITY-AND-EQUITY>                11,221,998
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                1,984,106
<OTHER-EXPENSES>                               167,129
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             249,921
<INCOME-PRETAX>                            (2,151,235)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,151,235)
<DISCONTINUED>                             (1,173,073)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (3,322,308)
<EPS-PRIMARY>                                   (1.47)
<EPS-DILUTED>                                   (1.47)
        

</TABLE>
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

JUDGMENT RENDERED APRIL 25, 2024

NO. 03-23-00044-CR

Alberto Torres, Appellant

v.

The State of Texas, Appellee

APPEAL FROM THE 450TH DISTRICT COURT OF TRAVIS COUNTY

BEFORE JUSTICES BAKER, TRIANA, AND KELLY

AFFIRMED -- OPINION BY JUSTICE BAKER

This is an appeal from the judgment of conviction entered by the trial court. Having reviewed 

the record and the parties’ arguments, the Court holds that there was no reversible error in 

the judgment. Therefore, the Court affirms the trial court’s judgment of conviction. Because 

appellant is indigent and unable to pay costs, no adjudication of costs is made.
Adrian M. BATTS, petitioner, v. UNITED STATES.

No. 12-9277.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.
AURORA LOAN SERVICES *A Lehman Brothers Company*Depositor: Structured Asset Securities Corporation 745 Seventh Avenue 8th Floor New York,  NY  10019 Trustee:    U.S. Bank National Association  One Federal Street 3rd Floor  Boston, M A  02110 Securities Administrator: Subject:  Annual Officer's Certification Fiscal Year:    2007 Securitization:  LXS 2007-1 6 N I, E. Todd Whittemore, the undersigned, a duly authorized officer of Aurora Loan Services LLC (the "Master Servicer"), do certify the following for the Calendar Year 2007: 1.A review of the  activities  of the Master Servicer during the period beginning on the cut-off date and ending on December 31, 2007 (the "reporting period") and of its performance under  the Agreement for such period has been made under m y supervision. 2.To the best of my knowledge, based on such review, the Master Servicer has fulfilled all of its obligations under the Agreement in all material aspects throughout such reporting period. Certified by: AURORA LOAN SERVICES LLC  By: /s/ E. Todd Whittemore Name:  E. Todd Whittemore Title: Executive Vice President
Anthony Rozelle BANKS, petitioner, v. Anita TRAMMELL, Interim Warden.

No. 12-9362.

Supreme Court of the United States

May 20, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.
Form Approved: OMB No. 0910-0025 

Expiration Date: February 28, 2026

DEPARTMENT OF HEALTH AND HUMAN SERVICES 

FOOD AND DRUG ADMINISTRATION

NOTICE OF AVAILABILITY OF SAMPLE ELECTRONIC PRODUCT

DATE

NOTE: This report is authorized by Public Law 90-602 for radiation-emitting products.

Paperwork Reduction Act Statement

Public reporting burden for this collection of information is estimated to average .09 hour per response, including the time for reviewing instructions,

searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments 

regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to:

Department of Health and Human Services 

Food and Drug Administration 

Office of Chief Information Officer 

Paperwork Reduction Act (PRA) Staff 

PRA Staff@fda.hhs.gov

<--Please DO NOT RETURN this application to this address.

"An agency may not conduct or sponsor, and a person is not required to respond to, 

a collection of information unless it displays a currently valid OMB control number."

The agrees to provide, on a loan basis and for 

a period of three to six months, the model(s) listed below for the purposes of compliance testing to the 

applicable FDA standard or in the case of medical devices, the applicable voluntary standard(s) specified 

in the attached letter. It is our understanding that the product(s) will be subjected to nondestructive testing 

only and that FDA will reimburse us for any costs of damaged parts.

1. MANUFACTURER 2. PRODUCT (i.e., TV, Microwave Oven, Medical Device, etc.)

3. BRAND 4. MODEL 5. CHASSIS SERIES

6. DATES OF AVAILABILITY:

a. Product b. Service Manual

7. COMMENTS

8. PERSON(S) TO CONTACT REGARDING SAMPLE

LOCATION A

Name and Title

Street Address

City, State, ZIP Code Area Code / Telephone No.

LOCATION B

Name and Title

Street Address

City, State, ZIP Code Area Code / Telephone No.

9. LOCATION(S) TO WHICH SAMPLE(S) SHOULD BE RETURNED

LOCATION A LOCATION B

10. NAME(S) OF PERSON(S) AUTHORIZING LOAN

LOCATION A

Name and Title

LOCATION B

Name and Title

RETURN 

TO:

Email this form to 

RadHealthCustomerService@fda.hhs.gov

or mail to:

Food and Drug Administration 

Center for Devices and Radiological Health 

10903 New Hampshire Ave., Document Mail Center - WO66-G609 

Silver Spring, MD 20993-0002

FORM FDA 2767 (06/23) PREVIOUS EDITION IS OBSOLETE PSC Publishing Services (301) 443-6740 EF
* Pursuant to Local Rule 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in Local Rule 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 97-40682 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus CARLYS COOPER, Defendant-Appellant.

- - - - - - - - - - Appeal from the United States District Court for the Eastern District of Texas USDC No. 9:96-CR-34-1

- - - - - - - - - - February 12, 1998 Before SMITH, EMILIO M. GARZA, and DeMOSS, Circuit Judges.
PER CURIAM: * Court-appointed counsel for Carlys Cooper has filed a brief as required by Anders v. California , 386 U.S. 738 (1967). Our independent review of the brief and the record discloses no nonfrivolous issue. Accordingly, counsel is excused from further responsibilities herein and the APPEAL IS DISMISSED.
**
**Exhibit 31.5**

**CERTIFICATION OF THE PRESIDENT AND CHIEF EXECUTIVE OFFICER**

**PURSUANT TO SECTION 302 OF**

**THE SARBANES-OXLEY ACT OF 2002**

I, RyanRhodes, President and Chief Executive Officer of Restoration Robotics, Inc., certify that: 

 
1.
I have reviewed this Amendment No. 2 to the Annual Report on Form10-K/A of Restoration Robotics, Inc.; and 

 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state amaterial fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 

 
Date: July 9, 2019  By: /s/ Ryan Rhodes   Ryan Rhodes   
President and Chief Executive Officer

(Principal Executive Officer)
**
# Fourth Court of Appeals

**San Antonio, Texas**

JUDGMENT

No. 04

- 18

- 00555

- CR

Avery B. CRAWFORD

, Appellant

v.

The STATE of Texas,

Appellee

From the 186th Judicial District Court, Bexar County, Texas

Trial Court No. 2017CR0602

Honorable Jefferson Moore, Judge Presiding

BEFORE CHIEF JUSTICE MARION

, JUSTICE WATKINS , AND JUSTICE RODRIGUEZ

In accordance with this court’s opinion of this date, the judgment of the trial court is

AFFIRMED.

SIGNED November 20, 2019.

_____________________________ Liza A. Rodriguez, Justice
EX-35.1
(logo) AVELO MORTGAGE



Annual Compliance Statement

Re: The Flow Servicing Agreement dated as of January 1, 2006 (the "Agreement"),
among Goldman Sachs Mortgage Company and Avelo Mortgage, LLC and GSAA Home
Equity Trust 2007-08.

1. A review has been completed of Avelo Mortgage, LLC's ("Avelo") servicing
activities and its performance under the servicing agreement during the period
from January 1, 2007 through December 31, 2007. This review was completed under
my supervision.

2. To the best of my knowledge, based on such review, Avelo has fulfilled all
of its obligations under the agreement in all material respects, except as
described in the item below:

Avelo acknowledges that for a period in 2007, bank accounts were not reconciled
in strict compliance with Reg. AB. To address this issue, Avelo added
additional staff to ensure timely reconciliations and compliance with Reg AB.
As of the date of the audit, all bank account reconciliations were current. No
issues were found or arose from the delay in reconciling the bank accounts.

Avelo also acknowledges that for a period in 2007, escrow funds were not
returned to the obligor within 30 calendar days of full repayment in compliance
with Reg. AB due to a system issue. A system enhancement erroneously affected
the refund check process. Once the issue was identified, the system was
corrected.

As of December 31, 2007, escrow fund refunds were returned to the obligor
within 30 calendar days of full repayment, and no issues were found or arose
from the delay in returning the funds to the account holders.

I certify this information to be true and correct to the best of my ability.


/s/ David M. Altshuler
Name: David M. Altshuler
Title: Vice President and CFO
Date: March 10, 2008



Avelo Mortgage, LLC     250 E. John Carpenter Fwy       Irving, Texas 75062
[Federal Register Volume 60, Number 91 (Thursday, May 11, 1995)]
[Notices]
[Page 25238]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11596]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health


Notice of Meeting of the Advisory Committee to the Director, NIH

    Pursuant to Pub. L. 92-463, notice is hereby given of the meeting 
of the Advisory Committee to the Director, NIH, May 31, 1995, 
Conference Room 10, Building 31, National Institutes of Health, 
Bethesda, Maryland 20892.
    The entire meeting will be open to the public from 10:00 a.m. to 
adjournment. The topics proposed for discussion include (1) Report on 
the Structure and Function of the Division of Research Grants; (2) 
Views from the NIH Basic Research Ombudsman and the NIH Clinical 
Research Emissary; (3) REGO II--Study of the Clinical Center; and (4) 
New Affirmative Action Plan. Attendance by the public will be limited 
to space available.
    Ms. Janice Ramsden, Program Assistant, Office of the Deputy 
Director, National Institutes of Health, 1 Center Drive MSC 0159, 
Bethesda, Maryland 20892-0159, telephone (301) 496-0959, fax (301) 496-
7451, will furnish the meeting agenda, roster of committee members, and 
substantive program information upon request. Any individual who 
requires special assistance, such as sign language interpretation or 
other reasonable accommodations, should contact Ms. Ramsden no later 
than May 24, 1995.

    Dated May 5, 1995.
Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 95-11596 Filed 5-10-95; 8:45 am]
BILLING CODE 4140-01-M
Charles Ronald LOCKLEAR, Jr., petitioner, v. UNITED STATES.

No. 12-9998.

Supreme Court of the United States

May 28, 2013.

*2757Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
----

| TRUSTEE:                                                                                                                                                                                 | DEPOSITOR:                                                                                                                                                                                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| LaSalle      Bank National Association135      South LaSalle Street, Suite 1625Chicago,      Illinois 60603Attn:      Global Securities and Trust Services, J.P. Morgan 2007-LDP11  | J.P.      Morgan Chase Commercial Mortgage Securities Corp.270      Park Avenue, 10th FloorNew      York, New York 10017Attn:      Dennis Schuh, Vice President,Telecopy      number: (212) 834-6593  |
|                                                                                                                                                                                     |                                                                                                                                                                                                       |
| RATING      AGENCIES:                                                                                                                                                                    | DIRECTING      CERTIFICATEHOLDER:                                                                                                                                                                          |
| Moody’s      Investors Service, Inc.7      World Trade Center250      Greenwich Street, 25th      FloorNew      York, NY 10007Attn:      Tracey Ferguson                           | American      Capital Strategies, Ltd2      Bethesda Metro Center, 14th FloorBethesda,      Maryland 20814Attn:      Doug Cooper                                                                      |

| (A)    |   | a      review of CWCAM’s activities during the period 7/5/2007-12/31/2007                                     |
|--------|--------|---------------------------------------------------------------------------------------------------------------------|
|   |   | and      of CWCAM’s performance under this Agreement has been made under      my supervision; and             |
| (B)    |   | to      the best of my knowledge, based on such review, CWCAM has      fulfilled                                    |
|   |   | all      its obligations under this Agreement in all material respects throughout      the      period noted above. |

----

----

----
Kenneth Dean FENDER, petitioner, v. FLORIDA.

No. 12-9773.

Supreme Court of the United States

June 17, 2013.

Petition for writ of certiorari to the Supreme Court of Florida denied.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 01-2205

In Re: WILLIE A. KEY,

Petitioner.

On Petition for Writ of Prohibition. (CA-01-3076)

Submitted: January 17, 2002 Decided: January 28, 2002

Before WILKINS and KING, Circuit Judges, and HAMILTON, Senior

Circuit Judge.

Petition denied by unpublished per curiam opinion.

Willie A. Key, Petitioner Pro Se.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Willie A. Key filed this petition for a writ of prohibition,

or in the alternative, a writ of mandamus, asking this court to

direct the district court to cease certain practices concerning the

treatment of pro se petitions and to increase the amount of time in

which parties may respond to a magistrate judge’s report and

recommendation. Key also asks this court to order the district

court to grant a hearing on his request for injunctive relief and

to refund his filing fee.

Mandamus is a drastic remedy to be used only in extraordinary

circumstances. Kerr v. United States Dist. Court, 426 U.S. 394,

402 (1976). Mandamus relief is only available when there are no

other means by which the relief sought could be granted, In re

Beard, 811 F.2d 818, 826 (4th Cir. 1987), and may not be used as a

substitute for appeal. In re Catawba Indian Tribe, 973 F.2d 1133,

1135 (4th Cir. 1992). The party seeking a writ of mandamus or

prohibition carries the heavy burden of showing that he has no

other adequate means to attain the relief he desires and that his

entitlement to such relief is clear and indisputable. Allied Chem.

Corp. v. Daiflon, Inc., 449 U.S. 33, 35 (1980); In re Braxton, 258

F.3d 250, 261 (4th Cir. 2001).

Key has failed to establish his right to such relief or that

he has no other adequate means of relief. Accordingly, we deny

Key’s petition for a writ of prohibition or mandamus, his request
3

for a hearing, and his request for refund of the filing fee. We

dispense with oral argument because the facts and legal contentions

are adequately presented in the materials before the court and

argument would not aid the decisional process.

PETITION DENIED
##### 



Exhibit 31.1
 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
      (a)
    
    Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being
prepared;(b)
    
    Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting
principles;(c)
    
    Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation;
and(d)
    
    Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal quarter that has
materially affected, or is reasonably likely to materially affect, the registrants internal
control over financial reporting; and
  (a)
    
    All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrants ability to record, process, summarize and report financial information; and(b)
    
    Any fraud, whether or not material, that involves management or other employees who have
a significant role in the registrants internal control over financial reporting.
 /s/ Kambiz HooshmandKambiz HooshmandPresident and Chief Executive OfficerDate: February 5, 2008
Office of Global Policy and Strategy 

OGPS STATEMENT

April 12, 2023

Xinjiang Uyghur Autonomous Region of the People’s

Republic of China

The FDA remains concerned about the human rights abuses occurring in the Xinjiang Uyghur 

Autonomous Region of the People’s Republic of China. Given these concerns, we would like to 

reiterate that the Federal Food, Drug, and Cosmetic Act requires clinical trials to obtain the 

legally effective, informed consent of human subjects as described in the Act and the FDA’s 

implementing regulations. For more information on the FDA’s human subject protection and 

good clinical practice requirements, please see, for example, 21 CFR Parts 312 (312.60 and 

312.120) and 314 (314.125(b)(16) and 314.150(b)(8)), 601 (601.2(a)), 812 (812.28(a)(1), 

812.30(b)(4), and 812.100), 814 (814.45(a)(5), 814.46(a)(4), and 814.118(a)(7)), and 860 

(860.260(c)(9)). These regulations are intended to protect the rights, safety, and welfare of 

human subjects and help ensure the integrity of clinical data that support marketing 

authorizations.

###